(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Atreca (BCEL) said late Thursday it appointed Stephen Gould as chief scientific officer. Gould comes to Atreca from Genentech where he most recently...
Atreca (BCEL) late Wednesday announced a corporate reorganization - including a 25% workforce reduction - that is expected to preserve enough funding to...
Atreca (BCEL) has an average rating of buy and price targets ranging from $4 to $25, according to analysts polled by Capital IQ. (MT Newswires covers...
| Address | 835 Industrial Road San Carlos, California 94070 |
| Phone | +1.650.595.2595 |
| Number of Employees | 85 |
| President, Chief Executive Officer & Director | John A. Orwin |
| Chief Financial Officer | Herbert C. Cross |
| Senior Vice President-Research | Daniel Emerling |
| Chief Scientific Officer | Stephen Gould |
| Price Open | $2.73 |
| Previous Close | $2.49 |
| 52 Week Range | $1.51 - 7.00 |
| Market Capitalization | $78.7 M |
| Shares Outstanding | 31.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/01/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.91 |
| Beta vs. S&P 500 | N/A |
| Revenue | $961.0 K |
| Net Profit Margin | -12,073.68% |
| Return on Equity | -75.17% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
